Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080364 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
A Phase 3 study, sponsored by vTv Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
NCT02080364: Clinical Trial Phase 3 study, sponsored by vTv Therapeutics.
NCT02080364 is a Phase 3 study that was terminated before completion, run by vTv Therapeutics. The registered enrollment target is 880 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02080364, a Phase 3 study, was terminated before completion, sponsored by vTv Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
Study Summary
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.
Primary Outcome
The ADAS-cog is a structured scale (approximately 40 minutes to complete) that evaluates memory, orientation, attention, reasoning, language and constructional praxis (Rosen, 1984). The ADAS-cog scoring range for the version used in this study is from 0 to 70, with higher scores indicating greater cognitive impairment.
Interventions
- DRUG Placebo
- DRUG Azeliragon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-06-01 |
| Phase | Phase 3 |
Why NCT02080364 stopped before completion
NCT02080364 is an interventional study that assigns participants to a tested intervention. The registered 880 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02080364 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02080364 about?
NCT02080364 is a clinical study titled "Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease". This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.
What is the current status of trial NCT02080364?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2015-04. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT02080364?
The interventions under investigation include: Placebo (DRUG), Azeliragon (DRUG).
Who is sponsoring clinical trial NCT02080364?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02080364's enrollment target sits among peer trials
880 367th of 2000 higher than 1,631 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
- NCT06580314 · 880 participants · Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia